CARotid plaqUe StabilizatiOn & Regression With Evolocumab.

Status Recruiting

Clinical Trial Summary

The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque morphological stabilization and regression as compared to traditional lipid lowering therapy (LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12 months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and cardiac events at 12 and 24 months

Clinical Trial Description

Optimal lipid-lowering therapy (LLT) is a mainstay for the therapeutic management of atherosclerotic vascular disease. Cardiac and cerebrovascular adverse events and progression of atherosclerosis are, indeed, reduced in proportion to the achieved LDL cholesterol (LDL-C) levels.In addition, regression of atherosclerotic plaques with optimal LLT has been observed. However, optimal LLT with statin and ezetimibe, might be limited by the onset of adverse effects (i.e. disabling myalgias, diarrhea) with are usually dose -dependent, and the maximum tolerated statin dose might be insufficient to reach the recommended LDL-C goals. The advent of proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) has allowed the achievement of very low LDL-C levels, and the fulfillment of the recommended LDL-C targets. However, while the experience with PCSK9i in patients with coronary artery disease has been wide, and coronary plaque regression has been documented, little is known regarding carotid plaque regression following therapy with PCSK9i. Only a few case reports have been published, and no observational study has been carried out so far. Furthermore, morphological carotid plaque stabilization has a prognostic role, and the possibility of its early achievement with PCSK9i may be relevant, especially in the context of percutaneous or surgical carotid interventions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04730973
Study type	Interventional
Source	Azienda Ospedaliera Ordine Mauriziano di Torino
Contact	Tiziana Claudia Aranzulla, MD
Phone	+390115085038
Email	taranzulla@mauriziano.it
Status	Recruiting
Phase	Phase 4
Start date	March 1, 2021
Completion date	March 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02124928` - Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis	N/A
Active, not recruiting	`NCT01597453` - NOR-SYS: The Norwegian Stroke in the Young Study	N/A
Completed	`NCT00744523` - Proximal Protection With The Mo.Ma Device During Carotid Stenting	N/A
Completed	`NCT00231231` - Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)	Phase 3
Completed	`NCT00597974` - Neurological Outcome With Carotid Artery Stenting	N/A
Completed	`NCT00587717` - The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue	N/A
Completed	`NCT02536378` - POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
Completed	`NCT02126982` - Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
Active, not recruiting	`NCT01445613` - Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy	N/A
Terminated	`NCT01414387` - Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting	N/A
Completed	`NCT00406055` - CHOICE: Carotid Stenting For High Surgical-Risk Patients	Phase 4
Completed	`NCT00403078` - SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
Terminated	`NCT01968226` - TRACER RGD-K5 Carotid Plaque Imaging Study	Phase 2
Completed	`NCT01685567` - Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure	Phase 3
Completed	`NCT00402740` - Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)	N/A
Completed	`NCT00287508` - Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)	Phase 4
Completed	`NCT00178672` - A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease	Phase 4
Recruiting	`NCT02850588` - SVS VQI TransCarotid Revascularization Surveillance Project
Completed	`NCT02759653` - Norwegian Carotid Plaque Study
Withdrawn	`NCT01042912` - Frequency Analysis of Carotid Artery Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

CARotid plaqUe StabilizatiOn and Regression With Evolocumab. — CARUSO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms